IMMUCELL CORP /DE/ (ICCC): Form 8-K filed 2026-11-13
- Accepted by EDGAR
- 2026-11-12 18:15 ET
- Event date
- 2026-11-12
- Accession no.
- 0001437749-26-036629
- Original filing
- SEC EDGAR filing index
AI summary of the filing text. It can contain mistakes; the original filing is authoritative.
ImmuCell reports third quarter results and terminates At-The-Market offering
ImmuCell reported unaudited third quarter 2026 product sales of approximately $8.0 million, up 46.0%, and net income of $953,000, compared to a net loss of $140,000 in the prior-year quarter. The company terminated its At-The-Market offering and said it negotiated a new $3 million line of credit, which it expects to sign during the fourth quarter of 2026.
- Third quarter 2026 product sales increased 46.0% to approximately $8.0 million.
- Net income was $953,000, or $0.10 per diluted share, compared to a net loss of $140,000 in the prior-year quarter.
- Gross margin increased to 44.2% from 42.9% in the prior-year quarter.
- ImmuCell terminated its At-The-Market offering and negotiated a new $3 million line of credit.
earningsfinancingequity offering
Items reported
- Item 2.02: Results of Operations and Financial Condition
The company publicly announced results of operations or financial condition for a completed period, most often a quarterly earnings release. The release itself is usually attached as Exhibit 99.1. Information under Item 2.02 is generally "furnished" rather than "filed". - Item 9.01: Financial Statements and Exhibits
Lists the financial statements, pro forma information and exhibits filed with the report. It almost always accompanies another Item and is rarely news on its own.
Documents
| Type | Description | Document |
|---|---|---|
| 8-K | FORM 8-K | iccc20261112_8k.htm |
| EX-99.1 | EXHIBIT 99.1 | ex_1044599.htm |
The summary above was generated by AI from the filing text and checked automatically against it. Read the original documents on SEC EDGAR. How to read an 8-K.